24.06.2019
- Continuing a buying spree that has added adding biologics and gene therapy capabilities to its manufacturing repertoire, California-based US drug developer Catalent is buying a...
26.04.2019
- US drug developer Catalent has announced plans to expand its integrated turnkey softgel capabilities at Eberbach, Germany, at a cost of $14 million up to 2020. The expansion...
16.04.2019
- As the series of multi-billion-dollar buyouts among Contract Development Manufacturing Organizations (CDMOs) continues, US drug developer Catalent has announced it will acquire...
25.02.2019
- Catalent appointed Kay Schmidt as senior vice president, Technical Operations. In this new role, Schmidt will report to Alessandro Maselli, who earlier this month was appointed as...
10.01.2019
- US-based Catalent is investing $200 million in its biologics business to expand drug substance manufacturing capacity and fill/finish capabilities at its sites in Madison...
19.09.2018
- Recently, the pharmaceutical contract development and manufacturing organization (CDMO) industry has been extremely active in M&A, as is the pharma and generics industry itself...
19.09.2018
- With its pending $425-million acquisition of Halo Pharmaceuticals, Cambrex joins other contract providers that have used acquisitions in recent years to build end-to-to end service...
04.07.2018
- US pharma Catalent has agreed to buy Juniper Pharmaceuticals, including UK-based Juniper Pharma Services, for $133 million, boosting its drug development activities. The addition...
